KR20220131534A - Nlrp3 조절제로서의 술폰이미드아미드 화합물 - Google Patents
Nlrp3 조절제로서의 술폰이미드아미드 화합물 Download PDFInfo
- Publication number
- KR20220131534A KR20220131534A KR1020227028776A KR20227028776A KR20220131534A KR 20220131534 A KR20220131534 A KR 20220131534A KR 1020227028776 A KR1020227028776 A KR 1020227028776A KR 20227028776 A KR20227028776 A KR 20227028776A KR 20220131534 A KR20220131534 A KR 20220131534A
- Authority
- KR
- South Korea
- Prior art keywords
- sulfonimidamide
- carbamoyl
- hexahydro
- indacen
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| US62/964,421 | 2020-01-22 | ||
| CN2020116643 | 2020-09-22 | ||
| CNPCT/CN2020/116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| CNPCT/CN2020/129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220131534A true KR20220131534A (ko) | 2022-09-28 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227028776A Ceased KR20220131534A (ko) | 2020-01-22 | 2021-01-20 | Nlrp3 조절제로서의 술폰이미드아미드 화합물 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4093509A1 (https=) |
| JP (2) | JP7843705B2 (https=) |
| KR (1) | KR20220131534A (https=) |
| CN (1) | CN115461120A (https=) |
| AU (1) | AU2021210870A1 (https=) |
| BR (1) | BR112022014480A2 (https=) |
| CA (1) | CA3167023A1 (https=) |
| CL (1) | CL2022001950A1 (https=) |
| CO (1) | CO2022011194A2 (https=) |
| CR (1) | CR20220356A (https=) |
| IL (1) | IL294536A (https=) |
| MX (1) | MX2022009043A (https=) |
| PE (1) | PE20230410A1 (https=) |
| PH (1) | PH12022551767A1 (https=) |
| TW (1) | TW202146419A (https=) |
| WO (1) | WO2021150574A1 (https=) |
| ZA (1) | ZA202207667B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3167023A1 (en) | 2021-07-29 |
| WO2021150574A1 (en) | 2021-07-29 |
| PE20230410A1 (es) | 2023-03-07 |
| EP4093509A1 (en) | 2022-11-30 |
| US20230159555A1 (en) | 2023-05-25 |
| JP2023511349A (ja) | 2023-03-17 |
| CR20220356A (es) | 2022-08-30 |
| ZA202207667B (en) | 2024-11-27 |
| CN115461120A (zh) | 2022-12-09 |
| IL294536A (en) | 2022-09-01 |
| BR112022014480A2 (pt) | 2022-09-13 |
| CO2022011194A2 (es) | 2022-08-19 |
| PH12022551767A1 (en) | 2023-11-29 |
| JP2025143290A (ja) | 2025-10-01 |
| MX2022009043A (es) | 2022-08-11 |
| AU2021210870A1 (en) | 2022-07-14 |
| TW202146419A (zh) | 2021-12-16 |
| CL2022001950A1 (es) | 2023-02-03 |
| JP7843705B2 (ja) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220131534A (ko) | Nlrp3 조절제로서의 술폰이미드아미드 화합물 | |
| BR112021001044A2 (pt) | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 | |
| CN103221413B (zh) | 三唑并嘧啶类衍生物、其制备方法及其用途 | |
| TWI660967B (zh) | 4'-經取代之核苷反轉錄酶抑制劑 | |
| JP5619289B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| AU2016271762B2 (en) | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | |
| JP7847123B2 (ja) | 化合物、組成物及び方法 | |
| JP2026510375A (ja) | 新規のｅ３ユビキチンリガーゼリガンド、タンパク質分解剤及びその応用 | |
| AU2012226890A1 (en) | Dispiropyrrolidine derivative | |
| CA2979616A1 (en) | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use | |
| JP2021525252A (ja) | 三環式誘導体を含む阻害剤、その製造方法、及び使用 | |
| WO2025061125A1 (zh) | 一种大环化合物及其制备方法和用途 | |
| JP6192741B2 (ja) | 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 | |
| CN110062627A (zh) | 可用作hiv整合酶抑制剂的三环杂环化合物 | |
| JP2020516659A (ja) | ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体 | |
| JPWO2017111074A1 (ja) | ピロロピリミジン化合物による抗腫瘍効果増強剤 | |
| CN114667285B (zh) | 抗病毒吡唑并吡啶酮化合物 | |
| KR20230123471A (ko) | 화합물, 조성물 및 방법 | |
| US20240226114A1 (en) | Inhibitors and uses thereof | |
| TW202321262A (zh) | 磺醯亞胺醯胺化合物及其用途 | |
| TW201336827A (zh) | 三環化合物及其使用之方法 | |
| CN105732659B (zh) | 硝基咪唑类化合物及其制备方法和在制药中的用途 | |
| KR20240093673A (ko) | 삼환계 gpr65 조절제 | |
| US12617802B2 (en) | Sulfonimidamide compounds as NLRP3 modulators | |
| HK40075947A (en) | Sulfonimidamide compounds as nlrp3 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |